On August 22, 2024 ImmuneOnco Biopharmaceuticals reported on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group (Press release, ImmuneOnco Biopharma, AUG 22, 2024, View Source [SID1234655702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reference is made to the announcement of the Company dated August 1, 2024, in relation to the entry into a license and collaboration agreement (the "License and Collaboration Agreement") dated August 1, 2024, between the Company and SynBioTx Inc.("SynBioTx").

The board (the "Board") of directors ("Directors", and each a "Director") of the Company is pleased to announce that the Company has received an upfront payment of US$10 million from SynBioTx in line with the License and Collaboration Agreement. Pursuant to the License and Collaboration Agreement, the Company expects to receive potential nearterm payments of up to US$40 million in the future, the earliest of which is expected to be received in September of 2024. Furthermore, the Company and SynBioTx have established a joint Clinical Development & Operations Committee and will actively advance the development of the IMM2510 and IMM27M.

ABOUT IMM2510
IMM2510, independently developed by the Group, is a bispecific molecule with a mAbTrap structure targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand 1 (PD-L1). IMM2510 can inhibit angiogenesis, leading to tumor shrinkage, and sensitize tumor cells to immune responses, while activating T cells, NK cells, and macrophages via the blockade of PD-L1/programmed cell death protein 1 (PD-1) interaction and the induction of Fc-mediated antibody-dependent cellular cytotoxicity (ADCC)/antibody-dependent cellular phagocytosis (ADCP) activity.

ABOUT IMM27M
IMM27M is a new generation cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)antibody with enhanced ADCC activity. It can induce potent immune responses targeting CTLA-4 overexpressed immune-suppressive Treg cells and promote Treg depletion from the tumor microenvironment (TME), thus enhancing T-cell antitumor response.

On August 22, 2024 Hanmi Pharmaceutical reported the company has signed a technology transfer agreement with domestic research and development company Novomedison for the BTK inhibitor ‘Poseltinib’ (Press release, Hanmi, AUG 22, 2024, View Source [SID1234649253]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the 14th, Hanmi Pharmaceutical announced in its ‘Semi-Annual Report’ that it had transferred Poseltinib to Novomedison on June 3rd through major contracts and research and development activities.

The technology transfer target region is the entire world. The total contract amount and the amount received were not disclosed under the agreement of both companies.

Novomedison is the new name of Genome Opinion, which signed a joint development agreement with Hanmi Pharmaceutical for Poseltinib in October 2021.

After signing the joint development agreement, Hanmi Pharmaceutical and Novomedison have signed a technology transfer agreement.

After signing the joint development agreement, Novomedison has been conducting an investigator-led clinical trial with a three-drug combination therapy using Poseltinib.

Poseltinib is a drug that Hanmi Pharmaceutical has been developing since 2010 for the indication of diffuse large B-cell lymphoma. It was exported to Eli Lilly in 2015, but the rights were returned in 2019 as its efficacy was not proven in phase 2 for patients with rheumatoid arthritis.

Since then, Hanmi Pharmaceutical has been conducting phase 2 domestic trials for follow-up development.

On August 22, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), reported that SIM0508, a DNA polymerase θ (Pol θ) small molecule inhibitor developed independently by the company, has received Clinical Trial Approval from the National Medical Products Administration of China (Press release, Jiangsu Simcere Pharmaceutical Company, AUG 22, 2024, View Source [SID1234648427]). This approval allows for the commencement of clinical trials to evaluate the efficacy of SIM0508 in treating locally advanced/metastatic solid tumor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Homologous recombination is a vital cellular process for repairing DNA double-strand breaks. When homologous recombination deficiency (HRD) occurs, genomic instability can lead to tumor development. HRD tumors rely on an alternative repair pathway called microhomology-mediated end joining (MMEJ), where Pol θ plays a crucial role. Interestingly, Pol θ is rarely expressed in normal tissues but highly expressed in various malignant tumor cells. By blocking Pol θ, we can disrupt the MMEJ pathway, precisely targeting HRD tumor cells while sparing normal cells.

SIM0508, a potent small molecule inhibitor, selectively targets and inhibits Pol θ, effectively blocking MMEJ repair and precisely inhibiting the proliferation of HRD tumor cells. SIM0508 also has potential synergy when used in combination with poly (ADP-ribose) polymerase (PARP) inhibitors or chemotherapeutic agents. Preclinical studies of SIM0508 revealed favorable oral pharmacokinetics and safety, with no evident hematologic toxicities. These findings suggest that combining SIM0508 with PARP inhibitors or chemotherapeutic agents carries a low risk of additive toxicity. The preclinical data were presented at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting.

Simcere Zaiming’s pipeline currently includes 13 innovative drug projects either in the clinical study stage or with clinical approval.

On August 22, 2024 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that members of the Company’s senior management team will participate in the following investor conferences in September 2024 (Press release, Zai Laboratory, AUG 22, 2024, View Source [SID1234646067]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday, September 19, 2024, 8:00 a.m. ET in Track 2
Location: New York, New York

On August 22, 2024 Vir Biotechnology Inc. (NASDAQ: VIR) reported that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City (Press release, Vir Biotechnology, AUG 22, 2024, View Source [SID1234646066]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.